A Płużańska - Concepedia

Author

A Płużańska

Also Known As

A Pluzanska, A Pluzańska, A Płuzańska, A Płużańska, A. G. Pluzanska, A. Pluzanska, A. Płuzanska, A. Płuzańska, A. Płużanska, A. Płużańska

164

Publications

18.3K

Citations

H-Index

Concepts

All Affiliations

Medical University of Lodz Helsinki University Hospital Lund University Uppsala University Hospital University of Helsinki

About

A Płużańska is an author at Medical University of Lodz specializing in oncology, medicine, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	18	2K
2	Health Sciences	4	4	307
3	Biochemistry	1	1	23
4	Biostatistics	1	1	86
5	Cell Biology	1	1	53

A Płużańska

Publications

2.5K

Citations

H-Index

Page 1

	Year	Citations
Doxorubicin and Paclitaxel Versus Fluorouracil, Doxorubicin, and Cyclophosphamide as First-Line Therapy for Women With Metastatic Breast Cancer: Final Results of a Randomized Phase III Multicenter Trial Jacek Jassem, Tadeusz Pieńkowski, A Płużańska, Journal of Clinical Oncology	2001	307
Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC) U. Gatzemeier, A Płużańska, A. Szczęsna, Journal of Clinical Oncology Advanced NsclcOncologyMedicineCancer ManagementChemotherapy	2004	300
Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group J Sjöström, Carl Blomqvist, Henning T. Mouridsen, European Journal of Cancer Breast OncologyOncologyAnthracycline FailureSequential MethotrexateBreast Cancer	1999	269
Founder Mutations in the BRCA1 Gene in Polish Families with Breast-Ovarian Cancer Bartłomiej Górski, Tomasz Byrski, Tomasz Huzarski, The American Journal of Human Genetics Breast OncologySomatic VariantPolish FamiliesGeneticsCancer Genomics	2000	257
An open randomised trial of second-line endocrine therapy in advanced breast cancer Carsten Rose, O. Vtoraya, A Płużańska, European Journal of Cancer Advanced Breast CancerBreast OncologyEndocrine OncologyMedicineSecond-line Endocrine Therapy	2003	192
Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): First report of overall surviva Kathy S. Albain, S. Nag, G. Calderillo-Ruiz, Journal of Clinical Oncology Overall SurvivaBreast OncologyCancer ManagementClinical EndpointCox Regression	2004	155
Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer Stephen Chan, N. Davidson, Elona Juozaitytė, Annals of Oncology Metastatic Breast CancerOncologyBreast OncologyMedicinePhase Iii Trial	2004	149
A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/interferon-α2a vs placebo/interferon- α2a as first-line therapy in metastatic renal cell carcinoma Bernard Escudier, P. Koralewski, A Płużańska, Journal of Clinical Oncology First-line TherapyUrologyGenitourinary CancerMedicineMetronomic Therapy	2007	120
First-line bevacizumab combined with reduced dose interferon-α2a is active in patients with metastatic renal cell carcinoma Bohuslav Melichar, P. Koralewski, Alain Ravaud, Annals of Oncology UrologyReduced Dose Interferon-α2aFirst-line BevacizumabGenitourinary CancerMedicine	2008	103
Prognostic value of quality of life scores for time to progression (TTP) and overall survival time (OS) in advanced breast cancer Minna‐Liisa Luoma, Liisa Hakamies‐Blomqvist, J Sjöström, European Journal of Cancer Quality Of LifeLife AssessmentOverall Survival TimeBreast OncologyLongevity	2003	86

Page 1